PANC-GRP-3001, 2023-503256-27-00: Open-label single-arm, multicenter clinical trial to evaluate patient acceptability of a new CREON formulation of Pancreas Powder gastro-resistant pellets in patients with cystic fibrosis suffering from pancreatic exocrine insufficiency. |
|
|
| Completed | 1 | 60 | Europe | Creon 25.000, harde maagsapresistente capsules 25.000 eenheden, Creon 50000 Ph.Eur. lipase units, Creon 25000 Ph.Eur. lipase units, Creon 10000 Ph.Eur. lipase units, Creon 75000 Ph.Eur. lipase units, Creon? 10000 Capsules | MEDA Pharma GmbH & Co. KG, Meda Pharma GmbH & Co. KG (A Viatris Company) Benzstra?e 1 61352 Bad Homburg, Germany | patients with cystic fibrosis suffering from pancreatic exocrine insufficiency | | | | |
NCT07314489: A Study on the Changes of Glucose Metabolism and Exocrine Function in Patients With Chronic Pancreatitis |
|
|
| Recruiting | 1 | 80 | RoW | Creon（Pancreatin Enteric-coated Capsules） | Shanghai Changzheng Hospital | Chronic Pancreatitis Pancreatic Exocrine Insufficiency Blood Glucose | 12/26 | 12/35 | | |
ChiCTR2400086621: Study on the efficacy and safety of pancreatic enzyme replacement therapy for total enteral nutrition-related diarrhea in moderately to severely active Crohn's disease |
|
|
| Recruiting | 1 | 100 | | The dosage of Creon (trypsin enteric-coated capsule) (according to the drug instruction manual): 1 tablet every time, once every 2 hours, 6 times a day, and then stop taking it for 4 weeks; Treat according to routine procedure. The control group did not receive trypsin replacement therapy | Department of Gastroenterology, Renmin Hospital of WuhanUniversity; Renmin Hospital of WuhanUniversity, self-finance | Crohn’s disease | | | | |
